Drug profile · INN
insulin glargine recombinant
TOUJEO SOLOSTAR
insulin glargine recombinant (TOUJEO SOLOSTAR) is a insulin receptor agonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — insulin glargine recombinant
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 5
- Data quality
- 0.84
Quick answer
insulin glargine recombinant (TOUJEO SOLOSTAR) is a insulin receptor agonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Insulin receptor agonist
Primary target: Insulin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Sanofi pipeline pdf: Dupixent, Lantus and 2026 catalysts
This plan frames a Sanofi pipeline pdf-style news brief around 2026 clinical catalysts, with Dupixent as the anchor asset and Lantus as a mature revenue base. It also clarifies the Sanofi Pasteur MSD joint venture structure and why the pipeline matters for analysts and BD teams.
FDA Approves LANGLARA Interchangeable Biosimilar to Lantus Insulin - Lannett Company Enters Diabetes Market
FDA approves LANGLARA as interchangeable biosimilar to Lantus insulin glargine, marking Lannett Company's entry into diabetes treatment market through Lanexa Biologics.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is insulin glargine recombinant?
insulin glargine recombinant (TOUJEO SOLOSTAR) is a insulin receptor agonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for insulin glargine recombinant?
TOUJEO SOLOSTAR is a marketed brand name for insulin glargine recombinant. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of insulin glargine recombinant?
insulin glargine recombinant has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.